Upregulation of miR-335-5p Contributes to Right Ventricular Remodeling via Calumenin in Pulmonary Arterial Hypertension

Right ventricular (RV) failure determines the prognosis in pulmonary arterial hypertension (PAH), but the underlying mechanism is still unclear. Growing evidence has shown that microRNAs participate in RV remodeling. This study is undertaken to explore the role of miR-335-5p in regulating RV remodeling induced by PAH. Two PAH models were used in the study, including the monocrotaline rat model and hypoxia/su5416 mouse model. miRNA sequencing and RT-qPCR validation identified that miR-335-5p was elevated in the RV of PAH rats. In vitro, miR-335-5p expression was increased after angiotensin II treatment, and miR-335-5p inhibition relieved angiotensin II-induced cardiomyocyte hypertrophy. The luciferase reporter assay showed that calumenin was a target gene for miR-335-5p. Pretreatment with miR-335-5p inhibitors could rescue calumenin downregulation induced by angiotensin II in H9C2 cells. Moreover, intracellular Ca2+ concentration and apoptosis were increased after angiotensin II treatment, and miR-335-5p inhibition decreased intracellular Ca2+ accumulation and apoptosis. Finally, in vivo miR-335-5p downregulation (antagomir miR-335-5p) attenuated RV remodeling and rescued calumenin downregulation under conditions of hypoxia/su5416 exposure. Our work highlights the role of miR-335-5p and calumenin in RV remodeling and may lead to the development of novel therapeutic strategies for right heart failure.

[1]  Xiang Song,et al.  Inhibition of Long Noncoding RNA SNHG20 Improves Angiotensin II-Induced Cardiac Fibrosis and Hypertrophy by Regulating the MicroRNA 335/Galectin-3 Axis , 2021, Molecular and cellular biology.

[2]  M. Simon,et al.  Current Understanding of the Right Ventricle Structure and Function in Pulmonary Arterial Hypertension , 2021, Frontiers in Physiology.

[3]  M. Chen,et al.  MicroRNA-21 regulates right ventricular remodeling secondary to pulmonary arterial pressure overload. , 2021, Journal of molecular and cellular cardiology.

[4]  Xiangning Cui,et al.  Qiliqiangxin prevents right ventricular remodeling by inhibiting apoptosis and improving metabolism reprogramming with pulmonary arterial hypertension. , 2020, American journal of translational research.

[5]  S. Archer,et al.  Identification of Long Noncoding RNA H19 as a New Biomarker and Therapeutic Target in Right Ventricular Failure in Pulmonary Arterial Hypertension , 2020, Circulation.

[6]  M. Humbert,et al.  In vivo miR-138-5p inhibition alleviates monocrotaline-induced pulmonary hypertension and normalizes pulmonary KCNK3 and SLC45A3 expression , 2020, Respiratory Research.

[7]  J. Klinger,et al.  Guidelines for the Treatment of Pulmonary Arterial Hypertension , 2020, Lung.

[8]  Qian Xu,et al.  Comprehensive Analyses of miRNA-mRNA Network and Potential Drugs in Idiopathic Pulmonary Arterial Hypertension , 2020, BioMed research international.

[9]  H. Ghofrani,et al.  Influence of gender in monocrotaline and chronic hypoxia induced pulmonary hypertension in obese rats and mice , 2020, Respiratory Research.

[10]  Q. Shan,et al.  Integrated microarray analysis to identify potential biomarkers and therapeutic targets in dilated cardiomyopathy , 2020, Molecular medicine reports.

[11]  C. Plass,et al.  Identification of Pparγ-modulated miRNA hubs that target the fibrotic tumor microenvironment , 2019, Proceedings of the National Academy of Sciences.

[12]  W. Seeger,et al.  Right heart failure in pulmonary hypertension: Diagnosis and new perspectives on vascular and direct right ventricular treatment , 2019, British journal of pharmacology.

[13]  S. Hallström,et al.  Epigenetic modulation of tenascin C in the heart: implications on myocardial ischemia, hypertrophy and metabolism. , 2019, Journal of hypertension.

[14]  P. Liu,et al.  Inhibition of Src activation reverses pulmonary vascular remodeling in experimental pulmonary arterial hypertension via Akt/mTOR/HIF‐1 signaling pathway , 2019, Experimental cell research.

[15]  H. Baharvand,et al.  Hsa-miR-335 regulates cardiac mesoderm and progenitor cell differentiation , 2019, Stem Cell Research & Therapy.

[16]  P. Mulder,et al.  Integrative System Biology Analyses Identify Seven MicroRNAs to Predict Heart Failure , 2019, Non-coding RNA.

[17]  M. Mazzorana,et al.  Calcium-Induced Protein Folding in Calumenin and Calmodulin. , 2019, Methods in molecular biology.

[18]  K. Piontek,et al.  Exosome miR‐335 as a novel therapeutic strategy in hepatocellular carcinoma , 2018, Hepatology.

[19]  Lisheng Li,et al.  Osthole attenuates right ventricular remodeling via decreased myocardial apoptosis and inflammation in monocrotaline‐induced rats , 2018, European journal of pharmacology.

[20]  N. Wu,et al.  Upregulation of miR-335 ameliorates myocardial ischemia reperfusion injury via targeting hypoxia inducible factor 1-alpha subunit inhibitor. , 2018, American journal of translational research.

[21]  T. Thum,et al.  MicroRNAs in right ventricular remodelling , 2017, Cardiovascular research.

[22]  Xin Guo,et al.  Calumenin relieves cardiac injury by inhibiting ERS-initiated apoptosis during viral myocarditis. , 2017, International journal of clinical and experimental pathology.

[23]  Yu Wang,et al.  Ibutilide treatment protects against ER stress induced apoptosis by regulating calumenin expression in tunicamycin treated cardiomyocytes , 2017, PloS one.

[24]  Chengwen Sun,et al.  Angiotensin-(1-7) attenuates angiotensin II-induced cardiac hypertrophy via a Sirt3-dependent mechanism. , 2017, American journal of physiology. Heart and circulatory physiology.

[25]  B. Dahal,et al.  miR-223-IGF-IR signalling in hypoxia- and load-induced right-ventricular failure: a novel therapeutic approach. , 2016, Cardiovascular research.

[26]  Zhiwei Huang,et al.  Inhibition of FGFR Signaling With PD173074 Ameliorates Monocrotaline-induced Pulmonary Arterial Hypertension and Rescues BMPR-II Expression , 2015, Journal of cardiovascular pharmacology.

[27]  P. Pibarot,et al.  Downregulation of MicroRNA-126 Contributes to the Failing Right Ventricle in Pulmonary Arterial Hypertension , 2022 .

[28]  Sebastien Bonnet,et al.  A miR-208–Mef2 Axis Drives the Decompensation of Right Ventricular Function in Pulmonary Hypertension , 2015, Circulation research.

[29]  D. Bernstein,et al.  Dynamic microRNA expression during the transition from right ventricular hypertrophy to failure. , 2012, Physiological genomics.

[30]  E. Olson,et al.  Therapeutic Inhibition of miR-208a Improves Cardiac Function and Survival During Heart Failure , 2011, Circulation.

[31]  D. H. Kim,et al.  Characterization of Calumenin-SERCA2 Interaction in Mouse Cardiac Sarcoplasmic Reticulum* , 2009, The Journal of Biological Chemistry.

[32]  D. H. Kim,et al.  Calumenin interacts with SERCA2 in rat cardiac sarcoplasmic reticulum. , 2008, Molecules and cells.

[33]  N. Rajewsky,et al.  Silencing of microRNAs in vivo with ‘antagomirs’ , 2005, Nature.